jasper therapeutics is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. jasper’s lead compound, jsp191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
Company profile
Ticker
JSPR
Exchange
Website
CEO
Bala Venkataraman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Amplitude Healthcare Acquisition Corp
SEC CIK
Corporate docs
IRS number
842984849
JSPR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-8
Registration of securities for employees
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
4 Mar 24
424B5
Prospectus supplement for primary offering
7 Feb 24
8-K
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
6 Feb 24
8-K
Material Modifications to Rights of Security Holders
4 Jan 24
8-K
Jasper Therapeutics, Inc. Announces Reverse Stock Split
2 Jan 24
Latest ownership filings
SC 13G
Avidity Partners Management LP
27 Mar 24
4
Jeetinder Singh Mahal
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
4
RON MARTELL
20 Feb 24
4
Jeetinder Singh Mahal
20 Feb 24
4
HERB CROSS
20 Feb 24
4
Edwin Jonathan Tucker
20 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Qiming U.S. Healthcare Fund II, L.P.
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 104.28 mm | 104.28 mm | 104.28 mm | 104.28 mm | 104.28 mm | 104.28 mm |
Cash burn (monthly) | 3.98 mm | (no burn) | 6.45 mm | 5.41 mm | 3.99 mm | 4.02 mm |
Cash used (since last report) | 27.43 mm | n/a | 44.46 mm | 37.25 mm | 27.51 mm | 27.69 mm |
Cash remaining | 76.86 mm | n/a | 59.82 mm | 67.04 mm | 76.77 mm | 76.59 mm |
Runway (months of cash) | 19.3 | n/a | 9.3 | 12.4 | 19.2 | 19.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 6 |
Closed positions | 21 |
Increased positions | 11 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 63.64 bn |
Total shares | 123.53 mm |
Total puts | 100.00 |
Total calls | 68.90 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Velan Capital Investment Management | 11.22 mm | $7.59 bn |
Biotechnology Value Fund L P | 9.90 mm | $18.32 mm |
BVF | 9.90 mm | $6.93 bn |
CG Carlyle Group Inc | 8.76 mm | $6.05 bn |
Qiming U.S. Ventures Management | 8.52 mm | $5.96 bn |
Soleus Capital Management | 8.30 mm | $5.81 bn |
Soleus Capital Master Fund | 6.25 mm | $10.88 mm |
Qiming U.S. Healthcare Fund II | 5.85 mm | $88.50 mm |
Sphera Funds Management | 5.69 mm | $3.98 bn |
Roche Finance | 4.62 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Jeetinder Singh Mahal | Voting Common Stock | Sell | Dispose S | No | Yes | 26.4358 | 900 | 23.79 k | 25,009 |
12 Mar 24 | Jeetinder Singh Mahal | Voting Common Stock | Option exercise | Acquire M | No | Yes | 7.1 | 900 | 6.39 k | 25,909 |
12 Mar 24 | Jeetinder Singh Mahal | Stock Option Voting Common Stock | Option exercise | Acquire M | No | Yes | 7.1 | 900 | 6.39 k | 16,472 |
15 Feb 24 | Herb Cross | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 17.95 | 40,000 | 718.00 k | 40,000 |
15 Feb 24 | Martell Ron | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 17.95 | 100,000 | 1.80 mm | 100,000 |
15 Feb 24 | Jeetinder Singh Mahal | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 17.95 | 40,000 | 718.00 k | 40,000 |
15 Feb 24 | Tucker Edwin Jonathan | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 17.95 | 45,000 | 807.75 k | 45,000 |
News
Evercore ISI Group Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $65
3 Apr 24
RBC Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $70
28 Mar 24
TD Cowen Initiates Coverage On Jasper Therapeutics with Outperform Rating
18 Mar 24
Jasper Therapeutics Announces New Data Presented On Briquilimab Conditioning In Patients With Fanconi Anemia
15 Mar 24
Oppenheimer Maintains Outperform on Jasper Therapeutics, Maintains $80 Price Target
7 Mar 24
Press releases
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
21 Mar 24
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
19 Mar 24
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
4 Mar 24
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
26 Feb 24